Blueprint Medicines Corp (NASDAQ:BPMC) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus target price of $47.50 for the company and are predicting that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also assigned Blueprint Medicines Corp an industry rank of 73 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research cut Blueprint Medicines Corp from a “hold” rating to a “sell” rating in a report on Tuesday, October 6th.

In other news, insider Christoph Lengauer sold 84,998 shares of Blueprint Medicines Corp stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $21.05, for a total transaction of $1,789,207.90. Following the transaction, the insider now owns 103,334 shares in the company, valued at $2,175,180.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Fmr Llc sold 287,415 shares of Blueprint Medicines Corp stock in a transaction on Friday, November 27th. The shares were sold at an average price of $21.48, for a total value of $6,173,674.20. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Blueprint Medicines Corp stock. Simplex Trading purchased a new position in shares of Blueprint Medicines Corp (NASDAQ:BPMC) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The hedge fund purchased 1 shares of the company’s stock, valued at approximately $0.

Shares of Blueprint Medicines Corp (NASDAQ:BPMC) opened at 15.51 on Tuesday. Blueprint Medicines Corp has a 1-year low of $15.41 and a 1-year high of $37.17. The stock has a 50 day moving average price of $21.49 and a 200-day moving average price of $24.19. The firm’s market cap is $420.32 million.

Blueprint Medicines Corp (NASDAQ:BPMC) last issued its earnings results on Monday, November 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.07. The company earned $3.43 million during the quarter, compared to analyst estimates of $1.83 million. On average, equities research analysts expect that Blueprint Medicines Corp will post ($4.62) earnings per share for the current fiscal year.

Blueprint Medicines Corporation (NASDAQ:BPMC) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V, active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company’s BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company’s Imatinib, which is an inhibitor of KIT and PDGFRa, is approved in SM and GIST. The Company’s other drug candidate is BLU-554, which targets FGFR4, a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.

12 Month Chart for NASDAQ:BPMC

Get a free copy of the Zacks research report on Blueprint Medicines Corp (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with MarketBeat.com's FREE daily email newsletter.